Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding: A NeuroPharm-1 study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding : A NeuroPharm-1 study. / Köhler-Forsberg, Kristin; Ozenne, Brice; Larsen, Søren V.; Poulsen, Asbjørn S.; Landman, Elizabeth B.; Dam, Vibeke H.; Ip, Cheng Teng; Jørgensen, Anders; Svarer, Claus; Knudsen, Gitte M.; Frokjaer, Vibe G.; Jørgensen, Martin B.

In: Translational Psychiatry, Vol. 12, No. 1, 273, 2022.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Köhler-Forsberg, K, Ozenne, B, Larsen, SV, Poulsen, AS, Landman, EB, Dam, VH, Ip, CT, Jørgensen, A, Svarer, C, Knudsen, GM, Frokjaer, VG & Jørgensen, MB 2022, 'Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding: A NeuroPharm-1 study', Translational Psychiatry, vol. 12, no. 1, 273. https://doi.org/10.1038/s41398-022-02034-5

APA

Köhler-Forsberg, K., Ozenne, B., Larsen, S. V., Poulsen, A. S., Landman, E. B., Dam, V. H., Ip, C. T., Jørgensen, A., Svarer, C., Knudsen, G. M., Frokjaer, V. G., & Jørgensen, M. B. (2022). Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding: A NeuroPharm-1 study. Translational Psychiatry, 12(1), [273]. https://doi.org/10.1038/s41398-022-02034-5

Vancouver

Köhler-Forsberg K, Ozenne B, Larsen SV, Poulsen AS, Landman EB, Dam VH et al. Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding: A NeuroPharm-1 study. Translational Psychiatry. 2022;12(1). 273. https://doi.org/10.1038/s41398-022-02034-5

Author

Köhler-Forsberg, Kristin ; Ozenne, Brice ; Larsen, Søren V. ; Poulsen, Asbjørn S. ; Landman, Elizabeth B. ; Dam, Vibeke H. ; Ip, Cheng Teng ; Jørgensen, Anders ; Svarer, Claus ; Knudsen, Gitte M. ; Frokjaer, Vibe G. ; Jørgensen, Martin B. / Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding : A NeuroPharm-1 study. In: Translational Psychiatry. 2022 ; Vol. 12, No. 1.

Bibtex

@article{b34ce42641f64ec3bd7379249da57ba0,
title = "Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding: A NeuroPharm-1 study",
abstract = "Concurrent anxiety is frequent in major depressive disorder and a shared pathophysiological mechanism between anxiety and other depressive symptoms is plausible. The serotonin 4 receptor (5-HT4R) has been implicated in both depression and anxiety. This is the first study to investigate the association between the cerebral 5-HT4R binding and anxiety in patients with depression before and after antidepressant treatment and the association to treatment response. Ninety-one drug-free patients with depression were positron emission tomography scanned with the 5-HT4R ligand [11C]-SB207145. Depression severity and concurrent anxiety was measured at baseline and throughout 8 weeks of antidepressant treatment. Anxiety measures included four domains: anxiety/somatization factor score; Generalized Anxiety Disorder 10-items (GAD-10) score; anxiety/somatization factor score ≥7 (anxious depression) and syndromal anxious depression. Forty patients were rescanned at week 8. At baseline, we found a negative association between global 5-HT4R binding and both GAD-10 score (p < 0.01) and anxiety/somatization factor score (p = 0.06). Further, remitters had a higher baseline anxiety/somatization factor score compared with non-responders (p = 0.04). At rescan, patients with syndromal anxious depression had a greater change in binding relative to patients with non-syndromal depression (p = 0.04). Concurrent anxiety in patients with depression measured by GAD-10 score and anxiety/somatization factor score is negatively associated with cerebral 5-HT4R binding. A lower binding may represent a subtype with reduced natural resilience against anxiety in a depressed state, and concurrent anxiety may influence the effect on the 5-HT4R from serotonergic antidepressants. The 5-HT4R is a promising neuroreceptor for further understanding the underpinnings of concurrent anxiety in patients with depression.",
author = "Kristin K{\"o}hler-Forsberg and Brice Ozenne and Larsen, {S{\o}ren V.} and Poulsen, {Asbj{\o}rn S.} and Landman, {Elizabeth B.} and Dam, {Vibeke H.} and Ip, {Cheng Teng} and Anders J{\o}rgensen and Claus Svarer and Knudsen, {Gitte M.} and Frokjaer, {Vibe G.} and J{\o}rgensen, {Martin B.}",
note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
doi = "10.1038/s41398-022-02034-5",
language = "English",
volume = "12",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "nature publishing group",
number = "1",

}

RIS

TY - JOUR

T1 - Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding

T2 - A NeuroPharm-1 study

AU - Köhler-Forsberg, Kristin

AU - Ozenne, Brice

AU - Larsen, Søren V.

AU - Poulsen, Asbjørn S.

AU - Landman, Elizabeth B.

AU - Dam, Vibeke H.

AU - Ip, Cheng Teng

AU - Jørgensen, Anders

AU - Svarer, Claus

AU - Knudsen, Gitte M.

AU - Frokjaer, Vibe G.

AU - Jørgensen, Martin B.

N1 - Publisher Copyright: © 2022, The Author(s).

PY - 2022

Y1 - 2022

N2 - Concurrent anxiety is frequent in major depressive disorder and a shared pathophysiological mechanism between anxiety and other depressive symptoms is plausible. The serotonin 4 receptor (5-HT4R) has been implicated in both depression and anxiety. This is the first study to investigate the association between the cerebral 5-HT4R binding and anxiety in patients with depression before and after antidepressant treatment and the association to treatment response. Ninety-one drug-free patients with depression were positron emission tomography scanned with the 5-HT4R ligand [11C]-SB207145. Depression severity and concurrent anxiety was measured at baseline and throughout 8 weeks of antidepressant treatment. Anxiety measures included four domains: anxiety/somatization factor score; Generalized Anxiety Disorder 10-items (GAD-10) score; anxiety/somatization factor score ≥7 (anxious depression) and syndromal anxious depression. Forty patients were rescanned at week 8. At baseline, we found a negative association between global 5-HT4R binding and both GAD-10 score (p < 0.01) and anxiety/somatization factor score (p = 0.06). Further, remitters had a higher baseline anxiety/somatization factor score compared with non-responders (p = 0.04). At rescan, patients with syndromal anxious depression had a greater change in binding relative to patients with non-syndromal depression (p = 0.04). Concurrent anxiety in patients with depression measured by GAD-10 score and anxiety/somatization factor score is negatively associated with cerebral 5-HT4R binding. A lower binding may represent a subtype with reduced natural resilience against anxiety in a depressed state, and concurrent anxiety may influence the effect on the 5-HT4R from serotonergic antidepressants. The 5-HT4R is a promising neuroreceptor for further understanding the underpinnings of concurrent anxiety in patients with depression.

AB - Concurrent anxiety is frequent in major depressive disorder and a shared pathophysiological mechanism between anxiety and other depressive symptoms is plausible. The serotonin 4 receptor (5-HT4R) has been implicated in both depression and anxiety. This is the first study to investigate the association between the cerebral 5-HT4R binding and anxiety in patients with depression before and after antidepressant treatment and the association to treatment response. Ninety-one drug-free patients with depression were positron emission tomography scanned with the 5-HT4R ligand [11C]-SB207145. Depression severity and concurrent anxiety was measured at baseline and throughout 8 weeks of antidepressant treatment. Anxiety measures included four domains: anxiety/somatization factor score; Generalized Anxiety Disorder 10-items (GAD-10) score; anxiety/somatization factor score ≥7 (anxious depression) and syndromal anxious depression. Forty patients were rescanned at week 8. At baseline, we found a negative association between global 5-HT4R binding and both GAD-10 score (p < 0.01) and anxiety/somatization factor score (p = 0.06). Further, remitters had a higher baseline anxiety/somatization factor score compared with non-responders (p = 0.04). At rescan, patients with syndromal anxious depression had a greater change in binding relative to patients with non-syndromal depression (p = 0.04). Concurrent anxiety in patients with depression measured by GAD-10 score and anxiety/somatization factor score is negatively associated with cerebral 5-HT4R binding. A lower binding may represent a subtype with reduced natural resilience against anxiety in a depressed state, and concurrent anxiety may influence the effect on the 5-HT4R from serotonergic antidepressants. The 5-HT4R is a promising neuroreceptor for further understanding the underpinnings of concurrent anxiety in patients with depression.

U2 - 10.1038/s41398-022-02034-5

DO - 10.1038/s41398-022-02034-5

M3 - Journal article

C2 - 35821015

AN - SCOPUS:85133901443

VL - 12

JO - Translational Psychiatry

JF - Translational Psychiatry

SN - 2158-3188

IS - 1

M1 - 273

ER -

ID: 314432480